Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
- PMID: 2360818
- PMCID: PMC171693
- DOI: 10.1128/AAC.34.5.792
Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
Abstract
The pharmacokinetics of vancomycin were evaluated in 34 patients (10 burn patients, 14 intravenous drug abusers [IVDA], and 10 controls). Multiple serum samples were drawn following a 1-h vancomycin infusion at steady state over an 8- to 12-h dosing interval. Pharmacokinetic parameters were derived by noncompartmental analysis. There were no significant differences among the groups with respect to age, weight, serum creatinine, volume of distribution, or protein binding. Burn patients had a significantly higher creatinine clearance than did IVDA or controls. Vancomycin clearances averaged 142.8, 98.0, and 67.7 ml/min in burn patients, IVDA, and controls, respectively. The renal clearance of vancomycin was also higher in burn patients than in the other groups. IVDA tended to have a higher vancomycin clearance (31% higher) than did controls, but the difference was not statistically significant. Vancomycin clearance was much higher in burn patients requiring dosage individualization and close monitoring. A considerable amount of vancomycin was eliminated through renal tubular secretion, making dosage predictions based on creatinine clearance more difficult. Further work with IVDA will be needed to determine if they represent a group requiring aggressive vancomycin dosages.
Similar articles
-
Vancomycin pharmacokinetics in patients with severe burn injuries.Burns. 2010 Jun;36(4):469-76. doi: 10.1016/j.burns.2009.08.010. Epub 2009 Oct 28. Burns. 2010. PMID: 19875238
-
Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.Burns. 2009 Feb;35(1):75-9. doi: 10.1016/j.burns.2008.05.016. Epub 2008 Sep 11. Burns. 2009. PMID: 18789586
-
Altered vancomycin dose vs. serum concentration relationship in burn patients.Clin Pharmacol Ther. 1988 Jul;44(1):9-13. doi: 10.1038/clpt.1988.105. Clin Pharmacol Ther. 1988. PMID: 3292106 Clinical Trial.
-
Simplified dosing and monitoring of vancomycin for the burn care clinician.Burns. 1992 Oct;18(5):355-61. doi: 10.1016/0305-4179(92)90032-p. Burns. 1992. PMID: 1445623 Review.
-
Pharmacokinetics of systemically administered antibiotics in patients with thermal injury.Clin Infect Dis. 1992 Feb;14(2):458-63. doi: 10.1093/clinids/14.2.458. Clin Infect Dis. 1992. PMID: 1554831 Review.
Cited by
-
Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.Antimicrob Agents Chemother. 1996 Mar;40(3):696-700. doi: 10.1128/AAC.40.3.696. Antimicrob Agents Chemother. 1996. PMID: 8851595 Free PMC article. Clinical Trial.
-
Pharmacokinetic optimisation of vancomycin therapy.Clin Pharmacokinet. 1995 Apr;28(4):327-42. doi: 10.2165/00003088-199528040-00005. Clin Pharmacokinet. 1995. PMID: 7648760 Review.
-
Augmented renal clearance: implications for antibacterial dosing in the critically ill.Clin Pharmacokinet. 2010;49(1):1-16. doi: 10.2165/11318140-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20000886 Review.
-
Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.Antimicrob Agents Chemother. 1992 May;36(5):1109-14. doi: 10.1128/AAC.36.5.1109. Antimicrob Agents Chemother. 1992. PMID: 1324637 Free PMC article. Clinical Trial.
-
Population pharmacokinetics of arbekacin in burn patients.Eur J Clin Pharmacol. 2008 Jun;64(6):599-603. doi: 10.1007/s00228-008-0470-1. Eur J Clin Pharmacol. 2008. PMID: 18320181
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical